Table 1: The inhibitory concentrations (IC50) of Strigolactone analogues for cancer cells.
Mean values are derived from 4 replicates of at least two independent experiments. The conversion between PPM and molarity is given for each analogue.
| Tumor Cell Lines | IC50 (ppm) at 72 h | ||||
| EG5 1ppm= 2.3 μM |
EG9C 1ppm=3.2 μM |
ST357 1 ppm=2.5 μM |
ST362 1 ppm=2.0 μM |
MEB55 1 ppm = 3.1 μM |
|
| Prostate PC3 DU145 LNCaP |
>15 13 >15 |
>15 >15 11.5 |
5.0 8.5 11.4 |
10.3 7.5 2.5 |
8.8 10.8 2.99 |
| Colon HT-29 HCT116 SW480 |
>15 >15 >15 |
>15 >15 >15 |
>15 >15 >15 |
7.3 5.2 2.9 |
8.2 10.4 9.7 |
| Lung A549 |
4.7 |
15.5 |
4.9 |
5.2 |
5.1 |
| Osteosarcoma U20S |
3.9 |
4.5 |
4.5 |
2.8 |
2.7 |
| Non-tumor cells BJ Fibroblasts |
ND |
>20 |
>20 |
ND |
>20 |